Specific Serotonergic Denervation Affects tau Pathology and Cognition without Altering Senile Plaques Deposition in APP/PS1 Mice
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Senile plaques and neurofibrillary tangles are major neuropathological features of Alzheimer's Disease (AD), however neuronal loss is the alteration that best correlates with cognitive impairment in AD patients. Underlying neurotoxic mechanisms are not completely understood although specific neurotransmission deficiencies have been observed in AD patients and, in animal models, cholinergic and noradrenergic denervation may increase amyloid-beta deposition and tau phosphorylation in denervated areas. On the other hand brainstem neurodegeneration has been suggested as an initial event in AD, and serotonergic dysfunction, as well as reductions in raphe neurones density, have been reported in AD patients. In this study we addressed whether specific serotonergic denervation, by administering 5,7-dihydroxitriptamine (5,7-DHT) in the raphe nuclei, could also worsen central pathology in APPswe/PS1dE9 mice or interfere with learning and memory activities. In our hands specific serotonergic denervation increased tau phosphorylation in denervated cortex, without affecting amyloid-beta (Aβ) pathology. We also observed that APPswe/PS1dE9 mice lesioned with 5,7-DHT were impaired in the Morris water maze test, supporting a synergistic effect of the serotonergic denervation and the presence of APP/PS1 transgenes on learning and memory impairment. Altogether our data suggest that serotonergic denervation may interfere with some pathological aspects observed in AD, including tau phosphorylation or cognitive impairment, without affecting Aβ pathology, supporting a differential role of specific neurotransmitter systems in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“We can not obviate that SP and Ab levels only characterize parts of a complex combination of pathological features, and the presence of soluble microscopic oligomeric forms of Ab, could be increased after the lesion, and could be responsible for detected cognitive alterations [52], since they likely contribute to the…”
BackgroundJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“APPswe/PS1dE9 mice have been widely used by the scientific community as animal models of AD, since they show SP deposition at 4–6 months of age [14,15] as well as learning and memory deficits by 8 months [16].”
MethodPropagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 1×
“composed by hyperphosphorylated tau and neuronal loss [1],”
BackgroundRapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · cited 1×
“order to study the relationship between these alterations, most of the studies have focused on the effect of Ab and tau pathology on neuronal morphology and function [2,3,5,28], however approach-”
BackgroundJin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 2×
“order to study the relationship between these alterations, most of the studies have focused on the effect of Ab and tau pathology on neuronal morphology and function [2,3,5,28], however approach-”
BackgroundCharacterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744 · cited 3×
“To our knowledge this specific has not been explored, however in our study selective serotonergic lesions did not interfere with Ab pathology in denervated areas, although our mice were lesioned when amyloid pathology is widely present in APPswe/PS1dE9 [14], as opposed to previously cited studies [35,50].”
MethodResultEnvironmental Enrichment Mitigates Cognitive Deficits in a Mouse Model of Alzheimer's Disease
Jankowsky, J. L., Melnikova, T., Fadale, D. J., Xu, G. M., Slunt, H. H., Gonzales, V., Younkin, L. H., Younkin, S. G., Borchelt, D. R., & Savonenko, A. V. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5080-04.2005 · Cited by 517 · cited 1×
“APPswe/PS1dE9 mice have been widely used by the scientific community as animal models of AD, since they show SP deposition at 4–6 months of age [14,15] as well as learning and memory deficits by 8 months [16].”
MethodRole of serotonin in memory impairment.
Buhot, M.-C., Martin, S., & Segu, L. (2000) · Annals of Medicine · doi:10.3109/07853890008998828 · Cited by 419 · cited 1×
“It has also been reported that serotonergic system role in cognition might be mediated by interacting with cholinergic, glutamatergic, dopaminergic or GABAergic neurotransmission [36].”
BackgroundCirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377
Cited by
Pathological mechanisms and therapeutic strategies for Alzheimer’s disease
Tam, K., & Ju, Y. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.320970 · Cited by 395
Dengler-Crish, C. M., Smith, M. A., & Wilson, G. N. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160658 · Cited by 61
Exercise-Induced Modulation of Neuroinflammation in Models of Alzheimer’s Disease
Kelly, Á. M. (2018) · Brain Plasticity · doi:10.3233/bpl-180074 · Cited by 55
“As with the APP point mutation models, there is no development of NFTs but hyperphosphorylation of Tau [60, 61] and neuronal loss [62] have been observed.”
InfluentialMechanistic complexities of bone loss in Alzheimer’s disease: a review
Frame, G., Bretland, K. A., & Dengler-Crish, C. M. (2020) · Connective Tissue Research · doi:10.1080/03008207.2019.1624734 · Cited by 44
Alzheimer’s Disease: The Alternative Serotonergic Hypothesis of Cognitive Decline
Vakalopoulos, C. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170364 · Cited by 34
Metadata
- Authors
- Ramos-Rodriguez, J. J., Molina-Gil, S., Rey-Brea, R., Berrocoso, E., & Garcia-Alloza, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-11-21
- Volume
- 8
- Issue
- 11
- Pages
- e79947
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2072525935
- Cited by
- 46
- References
- 17
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific Serotonergic Denervation Affects tau Pathology and Cognition without Altering Senile Plaques Deposition in APP/PS1 Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0079947
- The paper
- Ramos-Rodriguez, J. J., Molina-Gil, S., Rey-Brea, R., Berrocoso, E., & Garcia-Alloza, M. (2013). Specific Serotonergic Denervation Affects tau Pathology and Cognition without Altering Senile Plaques Deposition in APP/PS1 Mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0079947
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.